Serum Islet Cell Autoantibodies During Interferon α Treatment in Patients With HCV-Genotype 4 Chronic Hepatitis

Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic is...

Descripción completa

Detalles Bibliográficos
Autores principales: Badra, Gamal, Waked, Imam, Selmi, Carlo, Saleh, Saleh M., El-Shaarawy, Ahmed, Lotfy, Mahmoud
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270744/
https://www.ncbi.nlm.nih.gov/pubmed/16603440
http://dx.doi.org/10.1080/17402520600557867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270744/
https://www.ncbi.nlm.nih.gov/pubmed/16603440
http://dx.doi.org/10.1080/17402520600557867

Ejemplares similares